author-photo

David Blake

University of Dundee

34

Papers

871

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

2020 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (13)
An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
An integrative omics approach, for identification of bona fides PLK1 associated biomarker in Oesophgeal adenocarcinoma

2019 Current Cancer Drug Targets
Show All
- Source
- Cite
- Save
Citations (1)
The Meisenheimer complex as a paradigm in drug discovery: reversible covalent inhibition through C67 of the ATP binding site of PLK1

2018 Chemistry & Biology
Show All
- Source
- Cite
- Save
Citations (9)
Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1309: CYC065, a novel CDK2/9 inhibitor, is an effective inducer of cell death and synergizes with BCL2 and BET inhibitors in B-cell lymphoma, including double-hit lymphomas

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)